

## Neurolix Appoints Mark Corrigan, M.D. to Advisory Board

**Dana Point, 29 May, 2015** – Neurolix Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Mark Corrigan, M.D. to its Advisory Board. Dr. Corrigan is a seasoned life sciences executive with broad healthcare industry experience including CNS drug development.

Dr. Corrigan currently serves as Chairman of the Board of Epirus Biopharmaceuticals Inc., a public biopharmaceutical company. He has also served as CEO and director of Zalicus and its progenitor companies since December 2006. Prior to Zalicus, Dr. Corrigan served as executive vice president, research and development at Sepracor, Inc. (now known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company acquired by Pfizer, Inc. in 2003, most recently as group vice president of Global Clinical Research and Experimental Medicine. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of directors of Cubist Pharmaceuticals and Avanir Pharmaceuticals where he served as Chairman of the Scientific Affairs Committee of both companies. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center.

"It is a pleasure to welcome Mark to the Neurolix Advisory Board," commented Mark Varney, Ph.D., CEO, "Mark brings many years of experience and a deep knowledge of CNS research and development. We look forward to the insights he will provide to facilitate the advancement of our programs at Neurolix."

### **About Neurolix, Inc.**

Neurolix, located in Dana Point, California, is a privately held biotechnology company developing small molecule drugs for the treatment of neurological disorders such as Parkinson's disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at <http://www.neurolix.com>.

### **Forward Looking Statement**

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolix disclaims any intent or obligation to update these forward-looking statements.

### **PRESS CONTACTS**

Dr Mark Varney, CEO Neurolix,  
[contact@neurolix.com](mailto:contact@neurolix.com)